NEU 0.35% $20.17 neuren pharmaceuticals limited

Acadia, page-685

  1. 2,814 Posts.
    lightbulb Created with Sketch. 529
    Here are just a few Acadia facts that may be of interest:
    *There are just 7 trading days left before the Acadia 2Q 2024 Earnings Report is released.
    *Last night Acadia shares closed at $19.10 per share with volume up 32.6% compared to the 3-month average daily volume.
    *Acadia has not added any new products for revenue generation in the past 3 months and relies solely on Nuplazid and Daybue for revenue.
    *Nuplazid sales appear to be flat lining at best over the last 6 months with revenue dropping $14M last quarter compared to the one prior.
    *18 analysts average Acadia revenue estimates for Q2 2024 are at $236M with a low to high range being $225M to $241M.This average estimate is $30M above the Q1 2024 result and reflects an increase of 14.6% over that result.
    *Using Daybue percentage of total sales numbers for the past 2 quarter results against the above analyst revenue estimate indicates a Daybue revenue estimate for Q4 2024 at between $87M and $89M
    *Using a Nuplazid revenue estimate of $136M[up$6M from previous quarter] in the Q4 2024 estimate indicates that Daybue revenue must reach $100M to meet the above analyst estimate of 236M.
    Kens
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.